Smith & Nephew SNATS Revenue 2010-2024 | SNN

Smith & Nephew SNATS revenue for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • Smith & Nephew SNATS annual revenue for 2024 was $5.81B, a 4.7% increase from 2023.
  • Smith & Nephew SNATS annual revenue for 2023 was $5.549B, a 6.4% increase from 2022.
  • Smith & Nephew SNATS annual revenue for 2022 was $5.215B, a 0.06% increase from 2021.

Smith & Nephew SNATS Revenue 2010-2024 | SNN

  • Smith & Nephew SNATS annual revenue for 2024 was $5.81B, a 4.7% increase from 2023.
  • Smith & Nephew SNATS annual revenue for 2023 was $5.549B, a 6.4% increase from 2022.
  • Smith & Nephew SNATS annual revenue for 2022 was $5.215B, a 0.06% increase from 2021.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$215.2B
Boston Scientific (BSX)$153.3B
Stryker (SYK)$148.6B
EssilorLuxottica (ESLOY)$131.1B
Medtronic (MDT)$114.9B
Lonza Group Ag (LZAGY)$49.8B
Haleon (HLN)$43.1B
ResMed (RMD)$37.8B
GE HealthCare Technologies (GEHC)$34.8B
Agilent Technologies (A)$32.4B
Terumo (TRUMY)$23.9B
Koninklijke Philips (PHG)$23.7B
Insulet (PODD)$20B
Zimmer Biomet Holdings (ZBH)$18.4B
Baxter (BAX)$14.3B
Sunny Optical Technology (SNPTF)$10.4B
Demant (WILYY)$8.6B
Bio-Rad Laboratories (BIO)$6.7B
Lantheus Holdings (LNTH)$4.9B
Prestige Consumer Healthcare (PBH)$3.7B
Perrigo (PRGO)$3.7B
Haemonetics (HAE)$3.5B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Envista Holdings (NVST)$3.3B
ICU Medical (ICUI)$3B
LeMaitre Vascular (LMAT)$1.8B
QuidelOrtho (QDEL)$1.7B
AtriCure (ATRC)$1.4B
Acuren (TIC)$1.4B
AdaptHealth (AHCO)$1.2B